{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:48Z","timestamp":1761894768337},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.3816\/clm.2008.n.027","type":"journal-article","created":{"date-parts":[[2008,9,4]],"date-time":"2008-09-04T01:10:02Z","timestamp":1220490602000},"page":"202-204","source":"Crossref","is-referenced-by-count":2,"title":["Progress in Multiple Myeloma"],"prefix":"10.3816","volume":"8","author":[{"given":"Sundar","family":"Jagannath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.n.027_bib1","first-page":"31a","article-title":"MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma","volume":"110","author":"San Miguel","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib2","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.n.027_bib3","doi-asserted-by":"crossref","first-page":"31a","DOI":"10.1182\/blood.V110.11.75.75","article-title":"Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients \u2265 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled tirla, IFM 01\/01","volume":"110","author":"Hulin","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLM.2008.n.027_bib5","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in longterm survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.n.027_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.n.027_bib8","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib9","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.n.027_bib10","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib12","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib13","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.n.027_bib14","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or highdose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.n.027_bib15","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.n.027_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.n.027_bib17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CLM.2008.n.027_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"15 suppl","key":"10.3816\/CLM.2008.n.027_bib19","first-page":"455s","article-title":"Bortezomib\/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005\/01 trial","volume":"26","author":"Harousseau","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.n.027_bib20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2007-07-101212","article-title":"Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial","volume":"111","author":"Abdelkefi","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.n.027_bib21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155791901170244X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155791901170244X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T03:10:45Z","timestamp":1588907445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155791901170244X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S155791901170244X"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.n.027","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}